Advertisement
NVCT 外匯新聞
Nuvectis Pharma Says FDA Grants Orphan Drug Designation To NXP800 For Cholangiocarcinoma
Biopharmaceutical company Nuvectis Pharma, Inc. (NVCT) announced Thursday that NXP800 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of cholangiocarcinoma.
RTTNews
|
650天前
